Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Passive Income Stocks to Buy Right Now.
On November 13, Scotiabank began coverage of Bristol-Myers Squibb Company with a Sector Perform rating and set a price target of $45, as reported by The Fly.
In the third quarter of 2025, Bristol-Myers Squibb Company reported revenue of $12.22 billion, a 2.77% increase from the same period last year. The growth reflected strong demand across the business and exceeded analysts’ estimates by $422.1 million. Revenue from the company’s Growth Portfolio rose 18% to $6.9 billion.
CEO and Chairman Christopher Boerner noted that the company is raising its top-line guidance while keeping the midpoint of its bottom-line guidance unchanged. Full-year revenue guidance was increased by $750 million at the midpoint to a range of $47.5 billion to $48 billion, largely driven by the ongoing strength of the Growth Portfolio. The company expects gross margins to remain around 72%, with operating expenses projected at $16.5 billion. Legacy portfolio sales are still anticipated to decline 15%–17% for the year.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and manufactures innovative medicines to treat serious diseases.
READ NEXT: 15 Extreme Dividend Stocks to Buy According to Hedge Funds and 15 Overlooked Dividend Stocks to Buy Right Now.
